13 September 2019 - - Swiss pharmaceutical group Vifor Pharma has hired Dr Klaus Henning Jensen as chief medical officer and Member of the executive committee in January 2020, the company said.

Dario Eklund, chief commercial officer and member of the Executive Committee will leave the company at the end of September. A search for a successor is underway.

Jensen joins Vifor Pharma from Sanofi, where he has most recently been Global Therapeutic Area Head, responsible for diabetes, cardiovascular and metabolism development.

In his new role at Vifor Pharma, he will be responsible for Clinical Development, Drug Safety and Medical Affairs.

He completed studies in Biophysics at the University of Copenhagen, and qualified as a Physician in 2003 and holds an Executive MBA from Copenhagen Business School.

Vifor Pharma also announces the departure of Dario Eklund. Dario Eklund joined Vifor Pharma in 2014 as Head of Global Business Operations, before becoming chief commercial officer in 2017. He has decided to pursue opportunities outside of Vifor Pharma, and will leave the organisation by the end of September.

Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives.

The company develops, manufactures and markets pharmaceutical products for precision patient care.

Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care); Relypsa; and OM Pharma. Vifor Pharma Group is listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).